Invited Commentary
Low-Risk Papillary Thyroid Cancer Presents a Treatment Dilemma in the Dutch Healthcare System
Sean Johnson,
Sean Johnson
Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, 10029 New York, NY, USA
Search for more papers by this author Tracy Wang,
Corresponding Author
Tracy Wang
Medical College of Wisconsin, 8701 W Watertown Plank Road, 53226 Milwaukee, WI, USA
[email protected]Search for more papers by this author
Sean Johnson,
Sean Johnson
Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, 10029 New York, NY, USA
Search for more papers by this author Tracy Wang,
Corresponding Author
Tracy Wang
Medical College of Wisconsin, 8701 W Watertown Plank Road, 53226 Milwaukee, WI, USA
[email protected]Search for more papers by this author
First published: 24 December 2022
No abstract is available for this article.
References
- 1Lin JF, Rodriguez Schaap PM, Metman MJH, Nieveen van Dijkum EJM, Dickhoff C, Links TP, Kruijff S, Engelsman AF Thyroid lobectomy for low-risk 1–4 cm papillary thyroid cancer is not associated with increased recurrence rates in the dutch population with a restricted diagnostic work-up. World J Surg (2022) 10.1007/s00268-022-06813-5363030399726783
- 2Ramundo V, Di Gioia CRT, Falcone R et al. Diagnostic performance of neck ultrasonography in the preoperative evaluation for extrathyroidal extension of suspicious thyroid nodules. World J Surg (2020) 44(8): 2669–267410.1007/s00268-020-05482-632193621
- 3Ochoa J, Pitt SC Less-intensive management options for low-risk thyroid cancer. Endocrinol Metab Clin North Am (2022) 51(2): 351–36610.1016/j.ecl.2021.11.01835662445
- 4Pitt SC, Saucke MC, Roman BR, Alexander SC, Voils CI The influence of emotions on treatment decisions about low-risk thyroid cancer: a qualitative study. Thyroid (2021) 31(12): 1800–180710.1089/thy.2021.0323346417158721509
- 5Chen W, Li J, Peng S et al. Association of total thyroidectomy or thyroid lobectomy with the quality of life in patients with differentiated thyroid cancer with low to intermediate risk of recurrence. JAMA Surg (2022) 157(3): 200–20910.1001/jamasurg.2021.644234935859
